Accelrys acquires VelQuest for $35 million

4 January 2012

Scientific enterprise R&D software and services company Accelrys (Nasdaq: ACCL) says that it has acquired fellow USA-based privately-held VelQuest Corp for $35 million in an all-cash transaction.

VelQuest is the leader in paperless lab execution systems supporting current Good Manufacturing Practices (cGMP) for Food and Drug Administration-regulated industries including pharmaceuticals and biotechnology organizations. Accelrys' acquisition of VelQuest extends its software portfolio into the downstream pharmaceutical development Quality Assurance and Quality Control (QA/QC) space, offering significant productivity improvements, faster cycle times, lower operational costs and reduced compliance risks for regulated life sciences organizations.

Deal slightly dilutive to 2012 income

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK